Summit Therapeutics declined roughly 4% in the latest session, with the move tied to ongoing fallout from a Jefferies rating cut issued March 16, 2026. Jefferies downgraded SMMT to Hold and slashed its price target to $15 (from $42), citing heightened risk around multiple 2026 clinical and regulatory catalysts for ivonescimab and the potential for increased volatility into those events. �citeturn2search0turn1search5turn2search9

With the stock trading near the new $15 target, incremental sellers appear to be leaning into the view that the risk/reward has become less favorable ahead of binary trial milestones. The downgrade frames 2026 as a catalyst-heavy year where outcomes and timelines can swing valuation sharply, which can drive near-term de-risking even without a new company press release on the day. �citeturn2search0turn2search4turn1search6

Investors remain focused on Summit’s late-stage ivonescimab program and the cadence of 2026 updates. Separately, company filings indicate Summit has had an at-the-market equity sales program with capacity up to $1.0 billion through March 31, 2026, a detail that can heighten sensitivity to any perceived need for incremental funding given the company’s clinical-stage profile. �citeturn2search17turn1search4turn1search7